Biliary innate immunity: function and modulation

Area of Science:

• Immunology
• Gastroenterology
• Hepatology

Background:

• Biliary innate immunity, mediated by Toll-like receptors (TLRs), is crucial in cholangiopathies like primary biliary cirrhosis (PBC) and biliary atresia.
• Biliary epithelial cells recognize pathogen-associated molecular patterns (PAMPs), with tolerance to bacterial PAMPs but not double-stranded RNA (dsRNA).

Purpose of the Study:

• To investigate the role of biliary innate immunity in the pathogenesis of PBC and biliary atresia.
• To explore potential therapeutic targets for attenuating bile duct damage in these conditions.

Main Methods:

• Analysis of biliary innate immune responses in PBC and biliary atresia models.
• Evaluation of the involvement of CD4-positive Th17 cells, IL-17, and peroxisome proliferator-activated receptor-gamma (PPARgamma) in PBC pathogenesis.
• Investigation of the impact of dsRNA and associated pathways like tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and epithelial-mesenchymal transition (EMT) in biliary atresia.

Main Results:

• In PBC, Th17 cells and IL-17 contribute to chronic inflammation, linked to innate immune responses to PAMPs.
• Peroxisome proliferator-activated receptor-gamma (PPARgamma) is implicated in cholangitis, suggesting PPARgamma ligands as potential treatments.
• In biliary atresia, dsRNA viruses are suspected etiological agents, potentially inducing apoptosis via TRAIL and promoting EMT in biliary epithelial cells.

Conclusions:

• Biliary innate immunity significantly contributes to the pathogenesis of PBC and biliary atresia.
• Targeting PPARgamma may offer a therapeutic strategy for PBC by reducing bile duct inflammation and damage.
• Understanding the role of dsRNA in biliary atresia could lead to novel therapeutic interventions for this progressive cholangiopathy.